Document:

THIS
SECURITIES PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Zander Therapeutics, Inc., a Nevada corporation
(the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”),
a _______ whose address is _____________. 

WHEREAS:

The
Purchaser desires to purchase the common stock of the Company (“Shares”) in accordance with the terms and conditions
set forth herein.

The
Company desires to issue and sell Shares to the Purchaser in accordance with the terms and conditions set forth herein.

THEREFORE,
IT IS AGREED AS FOLLOWS

 

1.
Purchase Price

 

The
purchase price per Share ( “Purchase Price”), payable in US Dollars, shall be $2.50 per Share.

 

2.
Form of Payment

The
Purchaser shall pay the Purchase Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately
available funds to the Company

 

WIRE
INSTRUCTIONS:

________

_________

 

3.
Issuance of Stock

 

5
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares
purchased

 

4.
Purchaser’s Representations and Warranties

 

(a)
As of the date hereof, the Purchaser is purchasing the Units for its own account and not with a present view towards the public
sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933,
as amended ( the “Act”).

 

(b)
The Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under
the Act

 

(c)
The Purchaser and its advisors, if any, have been, furnished with all materials relating to the business, finances and operations
of the Company and materials relating to the offer and sale of the Units which have been requested by the Purchaser or its advisors.
Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information and will not
disclose such information unless such information is disclosed to the public prior to such disclosure to the Purchaser.

 

(d)
Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(e)
The execution, delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser’s breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of
or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument
to which the Purchaser is a party, or by which Purchaser is or may be bound.

 

5.
Company’s representations and warranties

 

(a)
Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and
has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(b)
The execution, delivery and performance of this Agreement by Company does not and shall not constitute Company’s breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of
or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument
to which the Company is a party, or by which Company is or may be bound.

 

6.
Restricted Securities Acknowledgement

 

Purchaser
acknowledges that any securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act
of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Act , and
shall contain the following restrictive legend:

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”

 

7.
Entire Agreement

 

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

 

8.
Governing Law, Venue, Waiver Of Jury Trial

 

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

 

IN
WITNESS WHEREOF, the parties have hereunto executed this Agreement on the 10th day of April, 2017.

By:

 

Zander
Therapeutics, Inc.

/s/
David Koos

David
Koos, CEO

	 

         

        Purchaser
	 	 
	 	 	 
	__________	 	 
	 	 	 
	 	 	 
	Number
    of Shares of Common Stock purchased	8,000	 	 
	Total
    Purchase Price:	$20,000AGREEMENT
BY AND BETWEEN ENTEST BIOMEDICAL, INC. AND THOMAS DONNELLY

Agreement
made on February 28, 2017 (“Execution Date”) by and between Thomas Donnelly (“Consultant”), a natural
person whose address is ___________and Entest BioMedical Inc.

(“Company”),
a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942. Consultant and Company may be referred
to individually as “Party” and collectively as “Parties”.

 

It
is agreed as follows:

 

1.
SCOPE OF SERVICES

Consultant
shall advise client on various nominal matters regarding veterinary biotechnology for the Company's wholly owned subsidiary Zander
Therapeutics Inc. "Nominal" is defined as periodic conversations in which Consultant is asked for a referral to an appropriate
researcher on a specific topic or input on research model the company is developing. In the event Consultant is requested to provide
research services, such services will be negotiated separately between Consultant and the Company.

 

2.
TERM

The
Term of this Agreement shall commence on March 1, 2017 and shall expire on February 29, 2018. The term of this Agreement may be
extended by mutual agreement.

 

3.
INDEPENDENT CONTRACTOR

The
Parties are independent contractors. Nothing in this Agreement shall be deemed to constitute a partnership or joint venture between
the Parties or constitute any Party to be the agent of the other Party for any purpose.

 

4.
NON-DISCLOSURE 

(a)
All information, whether in oral, written, graphic, electronic or other form, disclosed by the Company to the Consultant shall
be deemed to be “Proprietary Information.” In particular, Proprietary Information includes, without limitation, any
trade secrets, confidential information, ideas, inventions or research and development information; matters of a technical nature,
including technology; notes, products, knowhow, engineering or other data (including test data and data files); specifications,
processes, techniques, formulae or work-in-process; manufacturing, planning or marketing procedures, clinical data and regulatory
strategies or information; accounting, financial or pricing procedures or information, budgets

or
projections, or personnel or salary structure/compensation information; information regarding

suppliers,
clients, customers, employees, contractors, investors or investigators of the Company,

information
which has been designated in writing as confidential by the Company; programs, procedures (including operating procedures), processes,
methods, guidelines, policies, proposals or contracts; computer software, data bases or programming; and any other information
which, if divulged to a third party, could have an adverse impact on the Company, or on any third party to which it owes a confidentiality
obligation. In addition, “Proprietary Information” includes any of the foregoing relating to the past, present or
future operations, organization, projects, finances, business interests, methodology or affairs of any third party to which the
Company owes a duty of confidentiality including, without limitation, the mere fact that the Company is or may be working with
or for any client.

 

(b)
The obligations of confidentiality shall not apply to any Proprietary Information that was known by the Consultant at the time
of disclosure to it by such Company, or that is independently developed or discovered by the Consultant after disclosure by such
Company, without the aid, application or use of any item of such Company’s Proprietary Information, as evidenced by written
records; now, or subsequently becomes, through no act or failure to act on the part of the Consultant, generally known or available;
is disclosed to the Consultant by a third party authorized to disclose it; or is required by law or by court or administrative
order to be disclosed; provided, that the Consultant shall have first

given
prompt notice to such Company of such required disclosure.

 

(c)
Consultant shall exercise due care to prevent the unauthorized use or disclosure of the Company’s Proprietary Information,
and shall not, without the Company’s prior written consent, disclose or otherwise make available, directly or indirectly,
any item of the Company’s Proprietary Information to any person or entity other than those employees, independent contractors
or agents of the Consultant (collectively, “Representatives”), to the extent such Representatives reasonably need
to know the same in order to evaluate such Proprietary Information, to participate in the business relationship between the parties,
or to make decisions or render advice in connection therewith. Consultant shall advise its Representatives who have access to
the Company’s Proprietary Information of the confidential and proprietary nature thereof, and agrees that such Representatives
shall be bound by terms of confidentiality and restrictions on use with respect thereto that are at least as restrictive as the
terms of this Agreement.

 

(d)
Consultant shall exercise due care to prevent the unauthorized use or disclosure of the Company’s Proprietary Information,
and shall not, without the Company’s prior written consent, disclose or otherwise make available, directly or indirectly,
any item of the Company’s Proprietary Information to any person or entity other than those employees, independent contractors
or agents of the

Consultant
(collectively, “Representatives”), to the extent such Representatives reasonably need to know the same in order to
participate in any business relationship between the parties, or to make decisions or render advice in connection therewith. Consultant
shall advise its Representatives who have access to the Company’s Proprietary Information of the confidential and proprietary
nature thereof, and agrees that such Representatives shall be bound by terms of confidentiality and restrictions on use with respect
thereto that are at least as restrictive as the terms of this Agreement.

 

(e)
Consultant shall use the Company’s Proprietary Information solely for the purposes of performing his duties pursuant to
this Agreement and shall not make any other use of the Company’s Proprietary Information without the Company’s specific
written authorization.

 

(f)
All Proprietary Information of the Company (including all copies thereof) shall be and at all times remain the property of such
Company, and all non-oral Proprietary Information of the Company which is then in the Consultant’s possession or control
shall be destroyed or returned to the Company promptly upon its request at any time, and in any event, no later than 60 days following
any expiration or termination of this Agreement.

 

(g)
Nothing in this Agreement shall be construed, by implication or otherwise, as a grant of any right or license to trademarks, inventions,
copyrights or patents, as a grant of a license to either Consultant to use any of the Company’s Proprietary Information
except as expressly set forth herein.

 

(h)
The provisions of Section 4 of this Agreement shall survive until such time as all Confidential

Information
disclosed hereafter becomes publically known and made generally available through no action or inaction of Consultant.

 

5.
CONSIDERATION

As
consideration of the performance of services pursuant to this Agreement, Consultant shall receive:

(1)
Within 15 business days of the execution date of this Agreement Consultant shall be issued

100,000
shares of the Series B Preferred Stock of the Company (“Compensation Shares”).

 

(2)
Within 30 business days subsequent to the effective date of a Registration Statement filed

under
the Securities Act of 1933, as amended, registering common shares of Zander

Therapeutics,
Inc. (“Zander Registration Statement”) Consultant shall have the right to

exchange
up to the total number of the Compensation Shares issued to the Consultant

pursuant
to the terms and conditions of this Agreement for an equivalent number of the

common
shares of Zander Therapeutic, Inc. six months after Zander Therapeutics Inc. clears

a
registration statement. This right shall be withdrawn in the event of any breach of the terms

and
conditions of this Agreement by the Consultant.

 

(3)
Consultant acknowledges that nothing in this Agreement shall obligate either of the Company

or
Zander Therapeutics Inc. to register the common shares of Zander Therapeutics, Inc. under

the
Securities Act of 1933, as amended.

 

(4)
Consultant acknowledges that, in the event that a Zander Registration Statement is filed with

the
United States Securities and Exchange Commission (“SEC”), no assurance is given that

the
Zander Registration Statement will be declared effective by the SEC.

 

(5)
Consultant acknowledges that any securities issued pursuant to this Agreement that are not

registered
pursuant to the Securities Act of 1933 shall constitute “restricted securities” as that

term
is defined in Rule 144 promulgated under the Securities Act of 1933, and shall contain

the
following restrictive legend:

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF

1933,
AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF ANY STATE AND MAY

NOT
BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE

DISPOSED
OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT

UNDER
THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO

AN
AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH

LAWS
AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION

OF
COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE

PROPOSED
TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

 

6.
REPRESENTATIONS AND WARRANTIES OF COMPANY

(a)
Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and
has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(b)
The execution, delivery and performance of this Agreement by Company does not and shall not constitute Company’s breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of
or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument
to which the Company is a party, or by which Company is or may be bound.

 

7.
REPRESENTATIONS AND WARRANTIES OF CONSULTANT

(a)
Consultant has the requisite power and authority to enter into and perform his obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(b)
The execution, delivery and performance of this Agreement by Consultant does not and shall not constitute Consultant’s breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of
or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument
to which the Consultant is a party, or by which Company is or may be bound.

 

8.
NON-DISPARAGEMENT

Consultant
agrees that Consultant shall not, during the term of this Agreement, disparage the Company, the Company’s products, the
Company’s employees, or members of the Company’s board of directors. For purposes of this Agreement the term “disparage”
shall mean any negative comment, written or oral, about the Company, the Company’s products, the Company’s employees,
or members of the Company’s board of directors. . Nothing set forth in this Agreement shall prohibit or limit in any way
a Party’s right to accurately and honestly respond as required or to cooperate with any valid government, court or regulatory
order or request. The provisions of Section 8 of this Agreement shall survive until that date which is three years subsequent
to the end of the Term of this Agreement.

 

9.
WORK PRODUCT

Consultant
agrees that the Company is the sole and exclusive owner of all intellectual property, including copyrights, trademarks, patents,
inventions, work product and know-how, which may result from any work performed by the Consultant pursuant to this Agreement.
Consultant agrees that Consultant shall, upon request of the Company, execute, acknowledge, deliver and file any and all documents
necessary or useful to vest in the Company all of Consultant’s right, title and interest in and to all intellectual property,
including copyrights, trademarks, patents, inventions, work product and know-how, which may result from any work performed by
the Consultant pursuant to this Agreement. The term "Inventions" means all original works of authorship, developments,
concepts, improvements or trade secrets, whether or not patentable under law, that Consultant may individually or jointly conceive
or develop or reduce to practice, or cause to be conceived or developed or reduced to practice which may result from any work
performed by the Consultant pursuant to this Agreement

 

10.
SPECIFIC PERFORMANCE

Any
breach of this Agreement may result in irreparable damage to Company for which Company will not have an adequate remedy at law.
Accordingly, in addition to any other remedies and damages available, Consultant acknowledges and agrees that Company may immediately
seek enforcement of this Agreement by means of specific performance or injunction, without any requirement to post a bond or other
security.

 

11.
EXECUTION

This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same Agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.

 

12.
ENTIRE AGREEMENT

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

 

13.
SEVERABILITY

If
any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate
such substitute provision in this Agreement

 

14.
GOVERNING LAW, VENUE, WAIVER OF JURY TRIAL

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their

respective
authorized signatories as of the date first indicated above.

 

CONSULTANT

 

By:/s/Thomas
Donnelly

 

Date:
2/28/ 2017

 

COMPANY

By:
/s/David Koos

____________________

Its:
Chairman and CEO

Date:
March 10, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]